XOMA Royalty (XOMA) Liabilities and Shareholders Equity (2010 - 2026)
XOMA Royalty's (XOMA) quarterly Liabilities and Shareholders Equity came in at $271.9 million in Q1 2026, up 27.78% year-on-year from $212.8 million in Q1 2025, and little changed quarter-over-quarter from $272.7 million in Q4 2025.
XOMA Royalty (XOMA) Liabilities and Shareholders Equity (2010 - 2026) Analysis & Trends
XOMA Royalty has disclosed Liabilities and Shareholders Equity across 17 years of filings, most recently posting $271.9 million for Q1 2026.
- Liabilities and Shareholders Equity for Q1 2026 came in at $271.9 million, up 27.78% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.0 billion (up 14.49% YoY), and the FY2025 annual result was $272.7 million, up 23.24% from the prior year.
- Liabilities and Shareholders Equity came in at $271.9 million for Q1 2026 at XOMA Royalty, roughly flat from $272.7 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $272.7 million in Q4 2025 to a low of $124.1 million in Q3 2023.
- The 5-year median for Liabilities and Shareholders Equity is $219.4 million (2024), against an average of $198.2 million.
- Across the five-year window, Liabilities and Shareholders Equity fell 18.52% in 2023 and surged 93.6% in 2024, its largest moves.
- XOMA Royalty's Liabilities and Shareholders Equity stood at $140.4 million in 2022, then surged by 66.9% to $234.3 million in 2023, then fell by 5.56% to $221.3 million in 2024, then climbed by 23.24% to $272.7 million in 2025, then declined by 0.31% to $271.9 million in 2026.
- The last three Liabilities and Shareholders Equity figures came in at $271.9 million (Q1 2026), $272.7 million (Q4 2025), and $263.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | 37.37 Mn |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | 811.27 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 14.93 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 1.73 Bn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 33.89 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | 23.64 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 12.81 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 26.48 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 640.56 Mn |
| 10 | XOMA Royalty | 5.49 Mn | -60.59 Mn | - | 271.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 271.86 Mn |
| Dec 31, 2025 | 272.70 Mn |
| Sep 30, 2025 | 263.15 Mn |
| Jun 30, 2025 | 223.46 Mn |
| Mar 31, 2025 | 212.75 Mn |
| Dec 31, 2024 | 221.28 Mn |
| Sep 30, 2024 | 223.34 Mn |
| Jun 30, 2024 | 243.28 Mn |
| Mar 31, 2024 | 219.42 Mn |
| Dec 31, 2023 | 234.30 Mn |
| Sep 30, 2023 | 124.09 Mn |
| Jun 30, 2023 | 125.66 Mn |
| Mar 31, 2023 | 133.66 Mn |
| Dec 31, 2022 | 140.38 Mn |
| Sep 30, 2022 | 146.13 Mn |
| Jun 30, 2022 | 154.22 Mn |
| Mar 31, 2022 | 159.16 Mn |
| Dec 31, 2021 | 166.56 Mn |
| Sep 30, 2021 | 130.50 Mn |
| Jun 30, 2021 | 135.75 Mn |